首页> 外文期刊>Expert opinion on drug delivery >Nucleic acid vaccines: Prospects for non-viral delivery of mRNA vaccines
【24h】

Nucleic acid vaccines: Prospects for non-viral delivery of mRNA vaccines

机译:核酸疫苗:非病毒mRNA疫苗的前景

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Introduction: Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively evaluated in human clinical trials and have been shown to be safe and immunogenic, although none have been licensed for human use. More recently, mRNA-based vaccine alternatives have emerged and might offer certain advantages over their DNA-based counterparts. Areas covered: This review describes the two main categories of mRNA vaccines: conventional non-amplifying and self-amplifying mRNA. It summarizes the initial clinical proof-of-concept studies and outlines the preclinical testing of the next wave of innovations for the technology. Finally, this review highlights the versatile functionality of the mRNA molecule and introduces opportunities for future improvements in vaccine design. Expert opinion: The prospects for mRNA vaccines are very promising. Like other types of nucleic acid vaccines, mRNA vaccines have the potential to combine the positive attributes of live attenuated vaccines while obviating many potential safety limitations. Although data from initial clinical trials appear encouraging, mRNA vaccines are far from a commercial product. These initial approaches have spurred innovations in vector design, non-viral delivery, large-scale production and purification of mRNA to quickly move the technology forward. Some improvements have already been tested in preclinical models for both prophylactic and therapeutic vaccine targets and have demonstrated their ability to elicit potent and broad immune responses, including functional antibodies, type 1 T helper cells-type T cell responses and cytotoxic T cells. Though the initial barriers for this nucleic acid vaccine approach seem to be overcome, in our opinion, the future and continued success of this approach lies in a more extensive evaluation of the many non-viral delivery systems described in the literature and gaining a better understanding of the mechanism of action to allow rational design of next generation technologies.
机译:简介:正在开发基于核酸的疫苗,以结合减毒活疫苗和亚单位疫苗的积极特性。病毒载体和质粒DNA疫苗已经在人类临床试验中进行了广泛评估,并且已被证明是安全和具有免疫原性的,尽管没有一种许可用于人类。最近,基于mRNA的疫苗替代品出现了,并且可能比基于DNA的替代品具有某些优势。涵盖领域:本综述描述了mRNA疫苗的两个主要类别:常规非扩增和自扩增mRNA。它总结了最初的临床概念验证研究,并概述了该技术下一波创新的临床前测试。最后,本综述重点介绍了mRNA分子的通用功能,并为疫苗设计的未来改进提供了机会。专家意见:mRNA疫苗的前景非常广阔。像其他类型的核酸疫苗一样,mRNA疫苗有潜力结合减毒活疫苗的积极特性,同时消除了许多潜在的安全限制。尽管来自初始临床试验的数据似乎令人鼓舞,但mRNA疫苗远非商业产品。这些初始方法刺激了载体设计,非病毒传递,大规模生产和mRNA纯化的创新,从而使技术迅速发展。在临床前模型中已经针对预防性和治疗性疫苗靶标测试了一些改进,并证明了它们引发有效和广泛免疫应答的能力,包括功能性抗体,1型T辅助细胞,T型细胞应答和细胞毒性T细胞。尽管此核酸疫苗方法的最初障碍似乎已被克服,但在我们看来,该方法的未来和持续成功在于对文献中描述的许多非病毒递送系统进行了更广泛的评估,并获得了更好的理解。作用机制以合理设计下一代技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号